Skip to NavigationSkip to content

Johnson & Johnson

More quality issues dog J&J

Johnson & Johnson's manufacturing is under the spotlight at the FDA once again for quality issues affecting its products.

At the US regulator’s request, the drugmaker is recalling 43 over-the-counter medicines for infants and children made by its McNeil Consumer Healthcare division and distributed in the US and several other markets in the Americas and Middle East.

Cordis appoints Christian Spaulding

Published on: 30/03/10

Johnson & Johnson’s vascular technology company Cordis has appointed Dr Christian Spaulding worldwide VP of medical affairs.

He assumes the role, which will see him lead the company’s global clinical strategy, on 1 June and will be based in Paris.

“I’m excited to join Cordis,” said Spaulding. “As an interventional cardiologist, I’ve enjoyed working with the corporation as an investigator. I valued the company’s high quality standards for devices and ethics in clinical research.

J&J strengthens biotech business

 Johnson & Johnson is to expand its biotech capabilities with a $2.4 billion purchase of US company Scios.

The deal, still subject to regulatory and Scios Shareholder approval, will give J&J access to Scios' Natrecor, the first new agent for over a decade to treat congestive heart failure (CHF), and SCIO-469, a new type of kinase inhibitor to treat rheumatoid arthritis, in phase II trials.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches